Stock market today: S&P 500 rides Apple-led tech rally to close higher
Liquidia Corp (NASDAQ:LQDA), a $1.24 billion market cap biotech company, saw its Chief Human Resource Officer Sarah Krepp sell 2,673 shares of common stock on July 14, 2025, at a price of $14.28, for a total transaction value of $38,170. The sale comes amid a strong 13% gain in share price over the past week, with InvestingPro analysis indicating the stock is currently trading above its Fair Value.
The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 15, 2023. The shares were sold to cover taxes associated with the settlement of restricted stock units. Investors should note that Liquidia is scheduled to report its next earnings on August 7, 2025.
Following the transaction, Krepp directly owns 142,499 shares of Liquidia Corp, including unvested restricted stock units and shares acquired under the company’s employee stock purchase plan. The company maintains a healthy current ratio of 2.93, indicating strong ability to meet short-term obligations. For deeper insights into Liquidia’s financial health and detailed analysis, check out the comprehensive Pro Research Report available on InvestingPro.
In other recent news, Liquidia Corporation has received a substantial $50 million funding boost from Healthcare Royalty following a favorable court ruling and the commercial launch of its pulmonary hypertension treatment, YUTREPIA. This funding is part of a larger financing agreement, with a total of $175 million received out of a potential $200 million, contingent on future sales milestones. In a separate development, BTIG analysts have raised their price target for Liquidia’s stock to $45, maintaining a Buy rating, following the full FDA approval of YUTREPIA and the denial of United Therapeutics (NASDAQ:UTHR)’ injunction requests. Meanwhile, Raymond (NSE:RYMD) James reiterated a Strong Buy rating on Liquidia stock, despite competition from Insmed (NASDAQ:INSM)’s promising Phase 2b study results for its TPIP treatment in the same market. Additionally, Liquidia has appointed Dana Boyle as its new chief accounting officer, with an annual base salary of $425,000 and eligibility for performance-based bonuses and stock units. Boyle’s appointment is part of Liquidia’s strategic efforts to strengthen its executive team. As these developments unfold, investors are closely monitoring Liquidia’s progress in the competitive pulmonary hypertension market.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.